SK bioscience announced on the 18th that it has received approval for the clinical phase 1 and phase 3 trials of its 21-valent pneumococcal protein conjugate vaccine candidate, 'GBP410', in China. The company plans to enter phase 3 after completing phase 1 locally. SK bioscience and Sanofi are jointly developing GBP410. In a multinational phase 2 trial, it confirmed equivalent immunogenicity and safety to existing licensed vaccines. CEO Ahn Jae-yong noted, 'The approval of the clinical trial plan in China is another milestone following the expansion of the GBP410 production facility.'

Source : Chosun Biz(https://biz.chosun.com/en/)